IL282355A - Exosome-targeting bispecific antibodies - Google Patents

Exosome-targeting bispecific antibodies

Info

Publication number
IL282355A
IL282355A IL282355A IL28235521A IL282355A IL 282355 A IL282355 A IL 282355A IL 282355 A IL282355 A IL 282355A IL 28235521 A IL28235521 A IL 28235521A IL 282355 A IL282355 A IL 282355A
Authority
IL
Israel
Prior art keywords
exosome
bispecific antibodies
targeting bispecific
targeting
antibodies
Prior art date
Application number
IL282355A
Other languages
Hebrew (he)
Inventor
K Robinson Matthew
John Morin Michael
Original Assignee
Immunome Inc
K Robinson Matthew
John Morin Michael
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunome Inc, K Robinson Matthew, John Morin Michael filed Critical Immunome Inc
Publication of IL282355A publication Critical patent/IL282355A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
IL282355A 2018-10-17 2021-04-14 Exosome-targeting bispecific antibodies IL282355A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862746862P 2018-10-17 2018-10-17
PCT/US2019/056698 WO2020081786A1 (en) 2018-10-17 2019-10-17 Exosome-targeting bispecific antibodies

Publications (1)

Publication Number Publication Date
IL282355A true IL282355A (en) 2021-05-31

Family

ID=70284767

Family Applications (1)

Application Number Title Priority Date Filing Date
IL282355A IL282355A (en) 2018-10-17 2021-04-14 Exosome-targeting bispecific antibodies

Country Status (12)

Country Link
US (1) US20210347895A1 (en)
EP (1) EP3866851A4 (en)
JP (1) JP2022512734A (en)
KR (1) KR20210091714A (en)
CN (1) CN113423425A (en)
AU (1) AU2019359877A1 (en)
BR (1) BR112021007469A2 (en)
CA (1) CA3116560A1 (en)
IL (1) IL282355A (en)
MX (1) MX2021004036A (en)
SG (1) SG11202103812RA (en)
WO (1) WO2020081786A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3115149A1 (en) * 2018-10-02 2020-04-09 Immunome, Inc. Antibodies targeting epn1
CN114990129B (en) * 2022-05-11 2023-02-03 北京贝来生物科技有限公司 Preparation and application of mesenchymal stem cells expressing alpha PDL1: fc fusion protein
WO2023225613A2 (en) * 2022-05-18 2023-11-23 Immunome, Inc. Combination anti-epn1 and anti-pd-l1 antibody therapies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014209804A1 (en) * 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
BR112017010324A2 (en) * 2014-11-20 2018-05-15 F. Hoffmann-La Roche Ag method for treating or slowing cancer progression in an individual, molecules, methods for enhancing immune function in an individual and for selecting a patient for treatment, kits, pharmaceutical composition and uses of a combination of one molecule
CN108235685A (en) * 2015-07-29 2018-06-29 诺华股份有限公司 The combination of PD-1 antagonists and EGFR inhibitor
WO2017087280A1 (en) * 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CU24613B1 (en) * 2016-02-06 2022-07-08 Epimab Biotherapeutics Inc FABS TANDEM IMMUNOGLOBULIN BINDING PROTEINS (FIT-IG) BSPECIFIC BINDING TO CMET AND EGFR
CN109476741B (en) * 2016-03-25 2023-02-24 拜奥穆尼克斯制药 Molecules that bind to CD38 and PD-L1
CN108250302A (en) * 2016-12-29 2018-07-06 天津天锐生物科技有限公司 A kind of multifunctional protein

Also Published As

Publication number Publication date
KR20210091714A (en) 2021-07-22
CN113423425A (en) 2021-09-21
BR112021007469A2 (en) 2021-08-10
EP3866851A4 (en) 2022-11-02
SG11202103812RA (en) 2021-05-28
US20210347895A1 (en) 2021-11-11
CA3116560A1 (en) 2020-04-23
JP2022512734A (en) 2022-02-07
MX2021004036A (en) 2021-08-24
EP3866851A1 (en) 2021-08-25
WO2020081786A1 (en) 2020-04-23
AU2019359877A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
IL279235A (en) Dll3-cd3 bispecific antibodies
IL280780A (en) Anti-tigit antibodies
PL3519437T3 (en) Bispecific antibodies against p95her2
IL279352A (en) Il-11ra antibodies
IL280013A (en) Anti-il36r antibodies
IL278010A (en) Galectin-10 antibodies
GB201710838D0 (en) Bispecific antibodies
ZA202004908B (en) Bispecific antibody
IL277030A (en) Antibodies
SG11202106171WA (en) Anti-btla antibodies
SG11202007735TA (en) Anti-her2 antibodies
IL282756A (en) Humanized anti-sirpα antibodies
IL269577B (en) Anti-pd-l1-anti-tim-3 bispecific antibodies
IL282355A (en) Exosome-targeting bispecific antibodies
IL281594A (en) Anti-klrg1 antibodies
EP3693013A4 (en) Bispecific antibody
IL286757A (en) Bispecific antibodies
IL286918A (en) Bispecific antibody
GB201806084D0 (en) Antibodies
GB201911211D0 (en) Monoclonal antibodies against ambra-1
EP3728311A4 (en) Bispecific hiv-1-neutralizing antibodies
IL290050A (en) Bispecific antibody
ZA202206008B (en) Bispecific anti-ccl2 antibodies
GB201819952D0 (en) Antibodies
GB201817309D0 (en) Antibodies